Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.83M 3.34M 3.16M 2.87M 368M 5.39M 37.8M 14.59M 187M 14.4M 14.08M 602M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.49M 3.91M 3.7M 3.36M 431M 6.31M 44.27M 17.09M 219M 16.86M 16.49M 705M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| +0.11% | +2.71% | +0.33% | +28.59% | 46.28B | |
| -1.12% | +1.78% | +40.07% | +27.26% | 43.85B | |
| -3.04% | -6.29% | +322.27% | +517.36% | 40.93B | |
| -0.74% | +1.25% | +2.32% | +67.94% | 39.9B | |
| -0.50% | +0.67% | +11.79% | +40.51% | 29.5B | |
| -0.46% | +4.22% | +21.99% | +124.21% | 17.09B | |
| -0.97% | -10.17% | - | - | 15.55B | |
| -0.57% | +8.12% | +22.15% | +38.93% | 15.22B | |
| -3.14% | +31.91% | -10.60% | - | 14.05B | |
| Average | +0.22% | +3.76% | +51.29% | +120.69% | 29.15B | |
| Weighted average by Cap. | -1.02% | +1.87% | +64.69% | +130.23% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.14M -13.2M -12.47M -11.32M -1.45B -21.3M -149M -57.63M -739M -56.88M -55.62M -2.38B | 4.21M 3.01M 2.62M 2.47M 2.25M 288M 4.23M 29.64M 11.44M 147M 11.29M 11.04M 472M |
| Net Debt | 704K 503K 438K 414K 376K 48.22M 707K 4.96M 1.91M 24.52M 1.89M 1.85M 78.89M | 920K 657K 573K 541K 491K 63.02M 924K 6.48M 2.5M 32.04M 2.47M 2.41M 103M |
Employees
-
